Islamabad, Sep 9: Ferozsons Laboratories IPO BF Biosciences Limited’s application for listing has been approved by the Pakistan Stock Exchange (PSX) and the Securities and Exchange Commission of Pakistan (SECP).
Using the Book Building Method, a total of 25 million ordinary shares with a par value of Rs. 3 each will be issued in the Initial Public Offering, with a floor price of Rs. 55/-per share.
The Drug Regulatory Authority of Pakistan (DRAP) has granted BF Biosciences approval for its brownfield expansion (Line II), which includes a section dedicated to product development, a line of pre-filled syringes, and a line of liquid and lyophilized products.
While the liquid and lyophilized line is undergoing internal validation and will begin commercial production in the second quarter of FY 2024–2025, the pre-filled syringes line has already begun commercial production.
The pre-filled syringe version of sematide is now available from BF Biosciences Limited. The first Glucagon-Like Peptide 1 (GLP1) receptor agonist authorized for local manufacturing in Pakistan is sematide, which provides a practical diabetic control option.
Patients can use the pre-filled syringe with ease, and it eliminates dosing errors. Sematide is produced at BF Biosciences Limited’s brand-new, cutting-edge European prefilled syringes line.
